Compare BPRN & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BPRN | ACIU |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.5M | 235.1M |
| IPO Year | 2022 | 2015 |
| Metric | BPRN | ACIU |
|---|---|---|
| Price | $37.53 | $2.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 6.6K | ★ 285.1K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | ★ 74.84 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.96 | $706.75 |
| Revenue Next Year | $6.13 | $321.13 |
| P/E Ratio | $41.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.21 | $1.65 |
| 52 Week High | $37.99 | $4.00 |
| Indicator | BPRN | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 67.96 | 41.80 |
| Support Level | $33.78 | $2.03 |
| Resistance Level | N/A | $3.92 |
| Average True Range (ATR) | 0.46 | 0.15 |
| MACD | 0.28 | -0.00 |
| Stochastic Oscillator | 98.23 | 31.69 |
Princeton Bancorp Inc is a full-service financial institution providing personal and business banking services, including checking and savings accounts, as well as a range of lending products such as residential, commercial, construction, and consumer loans, including home equity loans and lines of credit. The Bank operates branches and conducts loan origination activities in areas of the New York City metropolitan area. Its loan portfolio is segmented into commercial real estate (including owner-occupied, non-owner-occupied, and multi-family properties), construction loans (mainly for residential developments), commercial and industrial loans (for business purposes), residential real estate loans (secured by one-to-four family properties), and consumer/HELOC loans.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.